Morgan Lewis partner Arianne Callender will present "The Crime of Doing Nothing: New Threats for Corporate Officers" at the ABA's upcoming live Webinar.
Recently, the FDA and The Office of the Inspector General (OIG) for the U.S. Department of Health & Human Services published guidance on the factors they will consider in determining whether to take action against individuals under this doctrine. In the past year, the OIG has excluded corporate executives of pharmaceutical companies-including a general counsel-based on misdemeanor Federal Food, Drug, and Cosmetics Act (FD&C Act) violations. This panel will examine the doctrine and proactive measures for use in avoiding or minimizing the risks involved.
Thursday, April 26, 2012
12 - 1:00 pm ET